{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:32:49Z","timestamp":1774265569723,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":746,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1016\/j.jhep.2010.11.012","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T10:40:58Z","timestamp":1291113658000},"page":"207-217","source":"Crossref","is-referenced-by-count":87,"title":["Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients"],"prefix":"10.1016","volume":"55","author":[{"given":"Nazia","family":"Selzner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Guindi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard L.","family":"Renner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2010.11.012_b0005","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jhep.2005.01.011","article-title":"What determines the natural history of recurrent hepatitis C after liver transplantation?","volume":"42","author":"Berenguer","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.11.012_b0010","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/lt.21646","article-title":"The natural history of recurrent hepatitis C and what influences this","volume":"14","author":"Gane","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0015","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.11.012_b0020","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jhep.2007.06.013","article-title":"Hepatitis C impairs survival following liver transplantation irrespective of concomitant hepatocellular carcinoma","volume":"47","author":"Melum","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.11.012_b0025","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jhep.2006.10.017","article-title":"Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation","volume":"46","author":"Picciotto","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.11.012_b0030","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1600-6143.2007.02126.x","article-title":"Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation","volume":"8","author":"Berenguer","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2010.11.012_b0035","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/TP.0b013e3181bd783c","article-title":"Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome","volume":"88","author":"Selzner","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2010.11.012_b0040","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/j.1600-6143.2006.01362.x","article-title":"Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis","volume":"6","author":"Wang","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2010.11.012_b0045","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2893.2008.01019.x","article-title":"Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies","volume":"15","author":"Xirouchakis","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2010.11.012_b0050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s10620-009-0981-3","article-title":"The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study","volume":"55","author":"Firpi","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2010.11.012_b0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/lt.21312","article-title":"Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon\/ribavirin therapy","volume":"14","author":"Hanouneh","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0060","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/lt.21760","article-title":"Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation","volume":"15","author":"Cescon","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0065","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/lt.20655","article-title":"Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients","volume":"12","author":"Berenguer","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(02)00398-0","article-title":"Signaling through the JAK\/STAT pathway, recent advances and future challenges","volume":"285","author":"Kisseleva","year":"2002","journal-title":"Gene"},{"key":"10.1016\/j.jhep.2010.11.012_b0075","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2010.11.012_b0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.biochi.2007.04.018","article-title":"The role of type I interferon production by dendritic cells in host defense","volume":"89","author":"Fitzgerald-Bocarsly","year":"2007","journal-title":"Biochimie"},{"key":"10.1016\/j.jhep.2010.11.012_b0085","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1440-1746.2008.05398.x","article-title":"Ribavirin in the treatment of chronic hepatitis C","volume":"23","author":"Martin","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2010.11.012_b0090","first-page":"55","article-title":"Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist\u2019s view","volume":"51","author":"Pellicano","year":"2005","journal-title":"Minerva Gastroenterol Dietol"},{"key":"10.1016\/j.jhep.2010.11.012_b0095","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1749-6632.2009.05138.x","article-title":"Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation","volume":"1183","author":"Kong","year":"2010","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.jhep.2010.11.012_b0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/jaut.1999.0360","article-title":"Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: a case-control study","volume":"14","author":"Ganne-Carrie","year":"2000","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhep.2010.11.012_b0105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1572-0241.2003.07269.x","article-title":"Is type II diabetes another extrahepatic manifestation of HCV infection?","volume":"98","author":"Mason","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.11.012_b0110","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3899\/jrheum.080874","article-title":"Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry)","volume":"36","author":"Ramos-Casals","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jhep.2010.11.012_b0115","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/lt.21635","article-title":"Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis","volume":"14","author":"Roche","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0120","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0049-0172(97)80005-4","article-title":"Hepatitis C virus infection and autoimmunity","volume":"26","author":"McMurray","year":"1997","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jhep.2010.11.012_b0125","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1002\/lt.20944","article-title":"Acute rejection in HCV-infected liver transplant recipients: the great conundrum","volume":"12","author":"Burton","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0130","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/00007890-199504150-00030","article-title":"Interferon-alpha-induced acute renal allograft rejection","volume":"59","author":"Magnone","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2010.11.012_b0135","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1159\/000189444","article-title":"Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C","volume":"74","author":"Rostaing","year":"1996","journal-title":"Nephron"},{"key":"10.1016\/j.jhep.2010.11.012_b0140","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1600-6143.2009.02702.x","article-title":"A practical guide to the management of HCV infection following liver transplantation","volume":"9","author":"Watt","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2010.11.012_b0145","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.11.012_b0150","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/lt.20189","article-title":"Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation","volume":"10","author":"Stravitz","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0155","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1172\/JCI115217","article-title":"Inhibition of immune functions by antiviral drugs","volume":"87","author":"Heagy","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2010.11.012_b0160","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2003.12.015","article-title":"Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination","volume":"40","author":"Dumortier","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.11.012_b0165","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/01.TP.0000129811.93072.1C","article-title":"Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy","volume":"78","author":"Neff","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2010.11.012_b0170","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1111\/j.1600-6143.2006.01470.x","article-title":"Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin","volume":"6","author":"Oton","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2010.11.012_b0175","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/lt.20883","article-title":"Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation","volume":"12","author":"Fernandez","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0180","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/gast.2003.50095","article-title":"Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study","volume":"124","author":"Samuel","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.11.012_b0185","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.20560","article-title":"Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials","volume":"41","author":"Chalasani","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.11.012_b0190","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study","volume":"132","author":"Carrion","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.11.012_b0195","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1053\/jlts.2003.50233","article-title":"Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection","volume":"9","author":"Kugelmas","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0200","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/TP.0b013e31819dfa83","article-title":"Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes","volume":"87","author":"McCaughan","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2010.11.012_b0205","doi-asserted-by":"crossref","unstructured":"Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997;25:658\u2013663.","DOI":"10.1002\/hep.510250328"},{"key":"10.1016\/j.jhep.2010.11.012_b0210","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1111\/j.1432-2277.1996.tb01606.x","article-title":"Is hepatitis C virus recurrence a risk factor for chronic liver allograft rejection?","volume":"9","author":"Charco","year":"1996","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2010.11.012_b0215","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1016\/j.transproceed.2005.10.060","article-title":"Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients","volume":"37","author":"Oton","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2010.11.012_b0220","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.TP.0000100481.14514.BB","article-title":"Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series","volume":"77","author":"Rodriguez-Luna","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2010.11.012_b0225","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/lt.20737","article-title":"Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C","volume":"12","author":"Berenguer","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0230","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/01.tp.0000269609.08495.45","article-title":"Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin","volume":"84","author":"Stanca","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2010.11.012_b0235","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/hep.510310337","article-title":"Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel","volume":"31","author":"Demetris","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.11.012_b0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00007890-199307000-00012","article-title":"Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection","volume":"56","author":"Matsumoto","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2010.11.012_b0245","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/gast.2001.24227","article-title":"Autoimmune hepatitis: clinical challenges","volume":"120","author":"Manns","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.11.012_b0250","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1053\/jlts.2002.33485","article-title":"Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance","volume":"8","author":"Czaja","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0255","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.21280","article-title":"Liver biopsy interpretation for causes of late liver allograft dysfunction","volume":"44","author":"Demetris","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.11.012_b0260","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1365-2249.2001.01682.x","article-title":"Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation","volume":"126","author":"Aguilera","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2010.11.012_b0265","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00007890-200107270-00018","article-title":"Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine","volume":"72","author":"Andries","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2010.11.012_b0270","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/jlts.2001.23792","article-title":"Concurrent de novo autoimmune hepatitis and recurrence of primary biliary cirrhosis post-liver transplantation","volume":"7","author":"Tan","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0275","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1053\/jhep.2002.31167","article-title":"Response to steroids in de novo autoimmune hepatitis after liver transplantation","volume":"35","author":"Salcedo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.11.012_b0280","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/01.tp.0000196716.07188.c4","article-title":"Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus","volume":"81","author":"Cholongitas","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2010.11.012_b0285","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00007890-200008150-00014","article-title":"Increased incidence of chronic rejection in adult patients transplanted for autoimmune hepatitis: assessment of risk factors","volume":"70","author":"Milkiewicz","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2010.11.012_b0290","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/lt.20706","article-title":"Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation","volume":"12","author":"Kontorinis","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0295","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/jlts.2003.50268","article-title":"Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C","volume":"9","author":"Wiesner","year":"2003","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0300","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/lt.20865","article-title":"Treating hepatitis C infection in liver transplant recipients","volume":"12","author":"Terrault","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0305","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jhep.2006.02.002","article-title":"Immunosuppression and outcomes of patients transplanted for hepatitis C","volume":"44","author":"Lake","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2010.11.012_b0310","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/lt.21447","article-title":"Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus","volume":"14","author":"Fiel","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0315","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/hupa.2002.32225","article-title":"Centrilobular histopathologic changes in liver transplant biopsies","volume":"33","author":"Khettry","year":"2002","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jhep.2010.11.012_b0320","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/lt.21949","article-title":"Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant","volume":"15","author":"Ward","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0325","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gut.2006.092064","article-title":"High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?","volume":"56","author":"Berardi","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2010.11.012_b0330","first-page":"185","article-title":"Prevalence of hepatitis C virus-associated mixed cryoglobulinemia after liver transplantation","volume":"6","author":"Abrahamian","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0335","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/lt.500020403","article-title":"Beneficial effect of ribavirin on hepatitis C-associated cryoglobulinemia after liver transplantation","volume":"2","author":"Safadi","year":"1996","journal-title":"Liver Transpl Surg"},{"key":"10.1016\/j.jhep.2010.11.012_b0340","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/0016-5085(92)90786-X","article-title":"Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C","volume":"102","author":"Shindo","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.11.012_b0345","first-page":"357","article-title":"Interferon alpha and autoimmunity","volume":"144","author":"Papo","year":"1993","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.jhep.2010.11.012_b0350","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/hep.1840220506","article-title":"Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver\u2013kidney microsomes","volume":"22","author":"Todros","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2010.11.012_b0355","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/0016-5085(95)90139-6","article-title":"Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C","volume":"108","author":"Garcia-Buey","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2010.11.012_b0360","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.3748\/wjg.15.5449","article-title":"G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence","volume":"15","author":"Lodato","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.11.012_b0365","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.3748\/wjg.v13.i32.4394","article-title":"Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment","volume":"13","author":"Kogure","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2010.11.012_b0370","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/lt.21518","article-title":"Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis?","volume":"14","author":"Demetris","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0375","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/lt.21451","article-title":"Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies","volume":"14","author":"Hubscher","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2010.11.012_b0380","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/lt.21404","article-title":"The prevalence and natural history of untreated isolated central perivenulitis in adult allograft livers","volume":"14","author":"Krasinskas","year":"2008","journal-title":"Liver Transpl"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827810010962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827810010962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T14:50:06Z","timestamp":1544107806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827810010962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0168827810010962"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2010.11.012","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}